Generic Name and Formulations:
Carboplatin 10mg/mL; soln for IV infusion.
Various generic manufacturers
- Motolimod Combination Therapy Does Not Improve Survival in Squamous Cell Carcinoma of the Head and Neck
- FDA Accepts sBLA for Pembrolizumab as Adjuvant Therapy for Melanoma
- Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in EGFR-Positive NSCLC
- Brain Cancer Treatment Regimens
- Thymomas and Thymic Carcinomas Treatment Regimens
- Testicular Cancer Treatment Regimens
Indications for Carboplatin:
Initial treatment of advanced ovarian cancer in combination with other chemotherapy. Secondary treatment of recurrent ovarian cancer after prior chemotherapy, including patients previously treated with cisplatin.
See literature. Give by IV infusion over ≥15 minutes. Combination therapy with cyclophosphamide (previously untreated): 300mg/m2 on Day 1 every 4 weeks for 6 cycles. As a single agent for recurrent ovarian carcinoma: 360mg/m2 on Day 1 every 4 weeks. In either case the Calvert equation may be used (Total Dose [mg]=[target area under the curve (AUC)] X [glomerular filtration rate + 25]). Use Calvert equation for elderly patients. Adjust dose for renal insufficiency and blood counts (see literature).
Severe bone marrow suppression. Significant bleeding. Pregnancy (Cat.D). Nursing mothers.
Dose-related bone marrow suppression. Elderly. Renal dysfunction. Monitor blood counts frequently; do not repeat dose until neutrophil count is >2,000 and platelets are >100,000. Anemia (transfusions may be needed). Premedicate with antiemetics; increasing infusion time or dividing total daily dose over 5 days may reduce emesis. Previous platinum-containing therapy. Loss of vision with higher than recommended doses.
Platinum coordination complex.
Potentiates nephrotoxicity with other nephrotoxic drugs (eg, aminoglycosides). Caution with other myelosuppressives.
Bone marrow suppression with possible infectious or hemorrhagic complications, anemia, vomiting, abdominal pain, anorexia, diarrhea, constipation, peripheral neuropathies, ototoxicity, visual disturbances, taste perversion, CNS symptoms, nephrotoxicity, hepatotoxicity, electrolyte changes, hypersensitivity reactions, injection site reactions, pain, asthenia, alopecia, malaise, hypertension; respiratory, genitourinary, mucosal, cardiovascular events; rare: hemolytic uremic syndrome.
Avoid contact with aluminum (eg, needles). Formerly known under the brand name Paraplatin.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?